Fig_5.tif (515.89 kB)

Relationship between post-treatment WFA⁺-M2BP values and HCC development.

figure

posted on 2015-06-12, 03:58 authored by Ryu Sasaki, Kazumi Yamasaki, Seigo Abiru, Atsumasa Komori, Shinya Nagaoka, Akira Saeki, Satoru Hashimoto, Shigemune Bekki, Yuki Kugiyama, Atsushi Kuno, Masaaki Korenaga, Akira Togayachi, Makoto Ocho, Masashi Mizokami, Hisashi Narimatsu, Tatsuki Ichikawa, Kazuhiko Nakao, Hiroshi Yatsuhashi

The distribution of WFA⁺-M2BP values was plotted. The dashed line indicates the 2.0 COI for WFA⁺-M2BP. The 16 patients who developed HCC were stratified according to the duration from SVR to HCC development in 5-year increments. Each time point is designated by a distinct symbol as indicated. 222 patients did not develop HCC, and 209 of these 222 patients (94.1%) were in the post-treatment WFA⁺-M2BP ≤ 2.0 COI group (white circles). During the follow-up period, 5 of 18 patients (27.8%) developed HCC in the post-treatment WFA⁺-M2BP > 2.0 COI group, which was significantly higher than the rate in the post-treatment WFA⁺-M2BP ≤ 2.0 COI group (5.0%, P < 0.001). In the post-treatment WFA⁺-M2BP > 2.0 COI group, 4 of 5 cases developed HCC within 5 years after IFN treatment (black circles).